Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Indivior Pharmaceuticals reported revenue of $1.2B in the fiscal year ended Dec 2025, up 4.3% from the year before. Operating income was $262M, an operating margin of 21.1%, and net income was $210M. Operating cash flow of −$27M less capital expenditure of $66M left free cash flow of −$93M. Net debt was $124M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 901 | 1,093 | 1,188 | 1,239 |
| Cost of revenue | 151 | 174 | 231 | 246 |
| Gross profit | 749 | 919 | 957 | 994 |
| Research & development | 74.0 | 116 | 107 | 97.0 |
| Selling, general & admin | 469 | 565 | 612 | 634 |
| Operating income | −81.0 | −152 | 38.0 | 262 |
| Interest expense | 27.0 | 35.0 | 41.0 | 45.0 |
| Pre-tax income | −89.0 | −145 | 20.0 | 239 |
| Income tax | −44.0 | −19.0 | 13.0 | 29.0 |
| Net income | −44.0 | −126 | 7.0 | 210 |
| Diluted EPS | −0.32 | −0.92 | 0.05 | 1.64 |
| Diluted shares | 139 | 137 | 133 | 128 |
| Fiscal year | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash & equivalents | 774 | 316 | 319 | 195 |
| Receivables | – | 254 | 254 | 253 |
| Inventory | – | 126 | 167 | 153 |
| Current assets | – | 1,257 | 827 | 652 |
| Net PP&E | – | 84.0 | 100 | 144 |
| Goodwill | – | 5.0 | 2.0 | 2.0 |
| Total assets | – | 1,758 | 1,316 | 1,201 |
| Payables | – | 39.0 | 63.0 | 48.0 |
| Current liabilities | – | 1,281 | 924 | 914 |
| Short-term debt | – | 3.0 | 18.0 | 29.0 |
| Long-term debt | – | 237 | 315 | 290 |
| Total liabilities | – | 1,942 | 1,652 | 1,300 |
| Shareholders' equity | −15.0 | −184 | −337 | −98.0 |
| Fiscal year | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating cash flow | −4.0 | −300 | 36.0 | −27.0 |
| Capital expenditure | 5.0 | 8.0 | 29.0 | 66.0 |
| Free cash flow | −9.0 | −308 | 7.0 | −93.0 |
| Depreciation & amortisation | 16.0 | 15.0 | 16.0 | 10.0 |
| Stock-based compensation | 16.0 | 21.0 | 24.0 | 26.0 |
| Acquisitions | 0.0 | 129 | 0.0 | 0.0 |
| Share buybacks | 90.0 | 33.0 | 173 | 11.0 |
| Fiscal year | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue growth (YoY) | – | 21.3% | 8.7% | 4.3% |
| Operating income growth (YoY) | – | – | – | 589.5% |
| EPS growth (YoY) | – | – | – | 3180.0% |
| Gross margin | 83.1% | 84.1% | 80.6% | 80.2% |
| Operating margin | −9.0% | −13.9% | 3.2% | 21.1% |
| Net margin | −4.9% | −11.5% | 0.6% | 16.9% |
| ROCEEBIT ÷ (assets − current liabilities) | – | −31.9% | 9.7% | 91.3% |
| Free cash flow margin | −1.0% | −28.2% | 0.6% | −7.5% |
| Cash conversion (CFO ÷ net income) | 0.09x | 2.38x | 5.14x | −0.13x |
| Receivable days | – | 85 | 78 | 75 |
| Inventory days | – | 264 | 264 | 227 |
| Payable days | – | 82 | 100 | 71 |
| Interest cover | −3.00x | −4.34x | 0.93x | 5.82x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | – | −76.0 | 14.0 | 124 |
| Current ratio | – | 0.98x | 0.90x | 0.71x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.